Trials / Withdrawn
WithdrawnNCT00255268
CMAB vs IMAB in Metastatic Prostate Cancer
Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Goserelin | |
| DRUG | Bicalutamide |
Timeline
- Start date
- 2004-08-01
- First posted
- 2005-11-18
- Last updated
- 2007-08-28
Locations
2 sites across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00255268. Inclusion in this directory is not an endorsement.